Showing all 13 results

  • Enhertu

    Enhertu

    $3,965.00

    Enhertu is a promising new treatment for patients with HER2-positive breast cancer.

    Its advanced effects, including a higher response rate, effectiveness in treating patients with brain metastases, and a manageable safety profile, make it an important addition to the treatment options available for these patients.

    Add to cartDone
  • Ibrance

    Ibrance

    $2,627.25 – $3,295.25

    Ibrance is a revolutionary medication that has transformed the treatment options for advanced breast cancer.

    Its unique mechanism of action and high efficacy have made it a popular choice among oncologists and patients alike.

    Select optionsDone
  • Kadcyla

    Kadcyla

    $3,444.22 – $5,519.54

    Kadcyla is an advanced treatment option for HER2-positive breast cancer that offers improved outcomes and fewer side effects compared to traditional chemotherapy.

    By targeting cancer cells specifically, this medication offers a more effective and precise approach to treating cancer and helping patients achieve a better quality of life.

    Select optionsDone
  • Keytruda

    Keytruda

    $3,573.57

    Keytruda (pembrolizumab) is a powerful targeted therapy that has shown great promise in treating advanced and metastatic cancers.

    Its ability to block the PD-1 pathway and stimulate the immune system’s response to cancer cells makes it a valuable tool in the fight against many types of cancer,

    Add to cartDone
  • Kisqali

    Kisqali

    $2,730.00

    Kisqali is a prescription medication that is used in the treatment of patients with HR+ breast cancer.

    The drug is taken in combination with an AI or fulvestrant and works by inhibiting the activity of CDK4/6 proteins, which are essential in the growth and division of cancer cells.

    Select optionsDone
  • Lynparza

    Lynparza

    $6,329.56

    Lynparza is a cutting-edge therapy that is expected to transform the cancer treatment space and change the lives of patients diagnosed with various forms of cancer.

    Lynparza precision and specificity guarantee that it targets only cancer cells while minimizing damage to healthy cells.

    Add to cartDone
  • Margenza

    Margenza

    $2,720.25

    Margenza is a promising new treatment option for patients with HER2-positive breast cancer, offering a significant improvement in clinical outcomes for patients with advanced HER2-positive breast cancer, who have already been treated with trastuzumab and pertuzumab therapy.

    The extended half-life of the drug and its potency offer better outcomes for patients, and the reduced frequency of dosing makes the treatment significantly more convenient for patients.

    Select optionsDone
  • Nerlynx

    Nerlynx

    $6,259.47

    Nerlynx is an advanced medication that offers new hope for patients with HER2-positive breast cancer who have completed trastuzumab-based therapy.

    Its ability to significantly reduce the risk of recurrence and delay the onset of brain metastases makes it a valuable treatment option for patients. 240 mg (6 tablets) taken once daily with food

    Add to cartDone
  • Perjeta

    Perjeta

    $2,036.09

    Perjeta is an advanced and highly effective medication for the treatment of HER2-positive breast cancer.

    The drug has been shown to have a significant impact on the progression of cancer, and is a key component of many breast cancer treatment plans.

    Add to cartDone
  • Piqray

    Piqray

    $7,700.00 – $10,500.00

    Piqray is an advanced medication that holds significant potential for improving the prognosis of patients with advanced breast cancer.

    Its ability to target the PI3K enzyme has shown great promise in preventing cancer growth and spreading to other parts of the body

    Select optionsDone
  • Tecentriq

    Tecentriq

    $4,125.77

    Tecentriq (Atezolizumab) represents a significant advancement in the treatment of cancer and other diseases.

    Its ability to enhance the immune response and modulate the immune system has enormous potential in a wide range of conditions beyond cancer.

    Add to cartDone
  • Trodelvy

    Trodelvy

    $4,685.80

    Trodelvy (sacituzumab govitecan-hziy) is a breakthrough medication that offers hope for patients with metastatic TNBC who have limited treatment options.

    The medication is highly effective, with clinically proven response rates, better overall survival, and a well-tolerated safety profile.

    Add to cartDone
  • Tukysa

    Tukysa

    $3,224.92 – $18,180.00

    Tukysa represents an important new option for the treatment of advanced HER2-positive breast cancer.

    By targeting the HER2 protein, Tukysa can help to slow the growth and spread of cancer cells, improving patient outcomes and extending survival.

    Select optionsDone